Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Essential thrombocythemia: a relative benign long-term course

S Meisel1, O Shpilberg, B Ramot

  • 1Department of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Israel Journal of Medical Sciences
|April 1, 1993
PubMed
Summary

Essential thrombocythemia, a blood disorder, often presents with neurological or thromboembolic symptoms. Treatment with medications like busulfan or hydroxyurea leads to prompt symptom relief and a generally favorable prognosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Invasive Aspergillosis in Neutropenic Patients with Hematological Disorders.

Leukemia & lymphoma·2016
Same author

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

Bone marrow transplantation·2015
Same author

Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation.

Transplant infectious disease : an official journal of the Transplantation Society·2015
Same author

International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis.

Bone marrow transplantation·2015

Area of Science:

  • Hematology
  • Oncology

Background:

  • Essential thrombocythemia is a myeloproliferative neoplasm characterized by elevated platelet counts.
  • Disease manifestations and treatment outcomes require further elucidation.

Purpose of the Study:

  • To evaluate disease manifestations, treatment response, and follow-up in essential thrombocythemia patients.
  • To assess the clinical course and prognosis of essential thrombocythemia under contemporary management.

Main Methods:

  • Retrospective analysis of 35 essential thrombocythemia patients.
  • Evaluation of presenting symptoms, platelet counts, treatment regimens (busulfan, hydroxyurea), and follow-up data.

Main Results:

  • Most patients presented with symptoms like neurological or thromboembolic events; hemorrhage was not a presenting symptom.

Related Experiment Videos

  • Cytoreductive therapy with busulfan or hydroxyurea resulted in prompt and sustained responses.
  • A significant proportion of symptomatic patients became asymptomatic after treatment, with no symptom recurrence.

    • Conclusions:

    • Essential thrombocythemia, while potentially serious, appears to have a more benign course with current treatments than previously suggested.
    • Effective management strategies can lead to significant symptom improvement and sustained remission.